introduct
accur
time
diagnosi
communityacquir
bacteri
infect
patient
system
inflamm
remain
challeng
clinician
laboratori
combin
marker
oppos
singl
one
may
improv
diagnosi
therebi
surviv
therefor
compar
diagnost
characterist
novel
routin
use
biomark
sepsi
alon
combin
method
prospect
cohort
studi
includ
patient
system
inflammatori
respons
syndrom
suspect
communityacquir
infect
conduct
medic
emerg
depart
depart
infecti
diseas
univers
hospit
multiplex
immunoassay
measur
solubl
urokinasetyp
plasminogen
activ
supar
solubl
trigger
receptor
express
myeloid
cell
strem
macrophag
migrat
inhibitori
factor
mif
use
parallel
standard
measur
creactiv
protein
crp
procalcitonin
pct
neutrophil
two
composit
marker
construct
one
includ
linear
combin
three
best
perform
marker
anoth
includ
six
area
receiv
oper
characterist
curv
auc
use
compar
perform
individu
marker
total
patient
elig
analysi
bacteri
infect
auc
detect
bacteri
caus
inflamm
confid
interv
ci
supar
ci
ci
mif
ci
pct
ci
neutrophil
count
ci
crp
ci
composit
threemark
test
ci
composit
sixmark
test
auc
sixmark
test
significantli
greater
singl
marker
combin
inform
sever
marker
improv
diagnost
accuraci
detect
bacteri
versu
nonbacteri
caus
inflamm
measur
supar
mif
limit
valu
singl
marker
wherea
pct
crp
exhibit
accept
diagnost
characterist
trial
registr
auc
area
receiv
oper
characterist
curv
ci
confid
interv
crp
creactiv
protein
icu
intens
care
unit
mif
macrophag
migrat
inhibitori
factor
pct
procalcitonin
roc
receiv
oper
characterist
sir
system
inflammatori
respons
syndrom
sofa
sequenti
organ
failur
assess
supar
solubl
receptor
urokinasetyp
plasminogen
activ
strem
solubl
trigger
receptor
express
myeloid
cell
bacteri
infect
sepsi
major
caus
morbid
mortal
medic
depart
intens
care
unit
icu
accur
time
diagnosi
infect
remain
challeng
clinician
laboratori
clinic
laboratori
sign
system
inflamm
includ
chang
bodi
temperatur
tachycardia
respiratori
rate
leucocytosi
sensit
howev
use
limit
poor
specif
diagnosi
sepsi
critic
ill
patient
often
present
system
inflammatori
respons
syndrom
sir
infect
issu
fuell
search
reliabl
marker
mani
potenti
biomark
investig
creactiv
protein
crp
procalcitonin
pct
current
use
routin
basi
search
singl
magic
bullet
marker
might
ultim
fruitless
combin
marker
could
improv
diagnosi
prognosi
treatment
efficaci
therebi
surviv
recent
discov
biomark
solubl
trigger
receptor
express
myeloid
cell
strem
known
upregul
phagocyt
cell
presenc
bacteria
fungi
found
sensit
specif
crp
pct
diagnos
sepsi
icu
patient
sir
valu
diagnos
sepsi
set
icu
remain
determin
anoth
novel
infecti
diseas
biomark
solubl
urokinasetyp
plasminogen
activ
receptor
supar
concentr
supar
increas
condit
involv
immun
activ
studi
shown
high
concentr
supar
portend
poor
clinic
outcom
divers
infect
tuberculosi
malaria
pneumococc
bacteraemia
final
cytokin
macrophag
migrat
inhibitori
factor
mif
found
valuabl
marker
microbiolog
document
infect
patient
undergon
cardiac
surgeri
elev
mif
concentr
may
earli
indic
poor
outcom
patient
sepsi
use
supar
mif
diagnos
communityacquir
bacteri
infect
medic
patient
yet
studi
undertook
present
studi
determin
discrimin
power
combin
multipl
marker
diagnos
bacteri
infect
adult
medic
patient
admit
hospit
suspect
communityacquir
infect
prospect
observ
studi
conduct
februari
februari
univers
hospit
consecut
newli
admit
hour
adult
patient
age
year
fulfil
least
two
criteria
sir
admit
depart
infecti
diseas
infecti
diseas
unit
medic
emerg
depart
ask
particip
princip
investig
studi
nurs
recruit
patient
collect
data
two
daili
round
week
day
base
data
obtain
week
day
estim
entir
studi
period
patient
admit
depart
infecti
diseas
home
admit
patient
fulfil
least
two
sir
criteria
inelig
particip
follow
reason
admiss
hour
evalu
referr
departmentshospit
failur
provid
inform
written
consent
age
year
refus
particip
reason
instanc
commun
problem
evalu
patient
includ
main
analysi
protocoldriven
procedur
blood
sampl
collect
data
later
calcul
admiss
simplifi
acut
physiolog
scale
ii
sequenti
organ
failur
assess
score
daili
record
temperatur
puls
rate
blood
pressur
respiratori
rate
one
week
mortal
rate
day
month
inclus
record
access
danish
civil
registr
system
patient
chart
blood
drawn
cubit
vein
vacutain
tube
becton
dickinson
plymouth
uk
directli
patient
inclus
sampl
follow
routin
hospit
procedur
perform
biotechnician
plasma
one
ml
coat
tube
separ
centrifug
store
one
week
transfer
later
analysi
pct
supar
mif
scientif
ethic
committe
copenhagen
frederiksberg
commun
approv
sampl
collect
basi
inform
written
consent
studi
protocol
regist
internet
patient
group
one
follow
four
group
infect
present
bacteri
infect
viral
infect
parasit
infect
classif
base
clinic
find
laboratori
find
respons
treatment
radiograph
imag
procedur
posit
neg
bacteriolog
viral
parasit
find
includ
cultur
polymeras
chain
reaction
serolog
antigen
test
perform
first
seven
day
admiss
expert
panel
consist
two
infecti
diseas
specialist
oa
gk
retrospect
review
medic
record
pertain
patient
independ
decid
diagnosi
time
admiss
precis
weight
find
greatli
depend
diseas
diagnos
instanc
chest
radiographi
diagnosi
respiratori
tract
infect
cerebrospin
fluid
cell
count
case
viral
mening
disagr
among
review
discuss
agreement
reach
consensu
panel
blind
pct
supar
mif
valu
instruct
disregard
crp
level
neutrophil
count
duplic
measur
plasma
supar
mif
perform
use
luminex
luminex
corp
austin
tx
usa
multiplex
assay
describ
detail
previous
margin
error
supar
mif
measur
respect
pct
plasma
concentr
measur
use
autom
sandwich
immunoassay
base
trace
timeresolv
amplifi
cryptat
emiss
techniqu
accord
manufactur
protocol
kryptor
brahm
diagnostica
berlinhenningsdorf
germani
crp
measur
plasma
standard
densiometri
vitro
irc
johnson
johnson
clinic
diagnost
inc
rochest
ny
usa
margin
error
pct
crp
assay
blood
leucocyt
neutrophil
count
measur
use
avida
devic
bayer
diagnost
tarrytown
ny
usa
margin
error
measur
respect
princip
investig
conduct
luminex
multiplex
assay
kryptor
assay
conduct
one
laboratori
technician
crp
leucocyt
assay
conduct
hospit
laboratori
technician
duti
patient
enrol
studi
studi
chose
use
cutoff
valu
mgl
cellsl
crp
pct
neutrophil
respect
cutoff
base
previous
report
find
cohort
similar
present
one
optim
supar
mif
threemark
sixmark
cutoff
valu
determin
use
youden
index
lack
refer
literatur
laboratori
paramet
includ
simplifi
acut
physiolog
scale
ii
sequenti
organ
failur
assess
score
analyz
depart
clinic
biochemistri
copenhagen
univers
hospit
hvidovr
denmark
follow
routin
procedur
measur
supar
mif
crp
pct
transform
use
logarithm
function
order
obtain
normal
distribut
within
diseas
group
neutrophil
count
transform
mannwhitney
utest
use
compar
concentr
singl
marker
patient
document
bacteri
infect
patient
undocu
bacteri
infect
sensit
specif
precis
confid
interv
ci
calcul
singl
composit
marker
inform
three
singl
best
perform
marker
six
marker
combin
use
method
report
xiong
cowork
identifi
linear
combin
marker
yield
greatest
area
receiv
oper
characterist
roc
curv
auc
led
construct
composit
threemark
test
composit
sixmark
test
optim
differenti
bacteri
nonbacteri
caus
inflamm
standard
error
auc
obtain
use
method
report
xiong
cowork
base
fisher
z
transform
diagnost
perform
composit
marker
compar
perform
singl
marker
use
auc
accord
method
suggest
hanley
mcneil
test
two
side
p
consid
statist
signific
data
analyz
use
statist
packag
r
version
r
develop
core
team
vienna
austria
figur
drawn
use
graphpad
prism
version
graphpad
softwar
san
diego
ca
usa
total
patient
fulfil
least
two
sir
criteria
includ
studi
exceed
time
limit
admiss
index
test
nonevalu
sampl
miss
data
withdraw
consent
patient
subsequ
exclud
remain
patient
clinic
demograph
characterist
comorbid
antibiot
treatment
admiss
summar
tabl
expert
panel
classifi
patient
infect
bacterium
viru
five
parasit
three
patient
blood
cultur
obtain
admiss
pathogen
bacterium
isol
blood
patient
admiss
first
seven
day
hospit
addit
cultur
conduct
urin
sputum
swab
skin
wound
mucos
stool
cerebrospin
fluid
patient
clinic
relev
pathogen
isol
patient
primari
site
infect
pathogen
isol
summar
tabl
patient
classifi
bacteri
infect
respiratori
system
absenc
microbi
document
chest
radiograph
find
suggest
bacteri
infect
patient
classifi
noninfect
caus
sir
respiratori
distress
lung
oedema
chronic
obstruct
pulmonari
diseas
copd
exacerb
sign
infect
embolu
lung
n
malign
diseas
n
intracrani
haemorrhag
n
allerg
reaction
n
metabol
acidosi
n
noninfecti
pancreat
n
gout
n
use
impur
intraven
drug
n
ruptur
mitral
valv
chorda
n
ruptur
thorac
aneur
n
castleman
diseas
n
addison
diseas
n
subileu
n
polymyos
n
final
three
patient
explan
sir
found
disagr
among
review
case
consensu
seven
classifi
noninfect
two
bacteri
infect
two
viral
infect
total
patient
given
antibiot
first
hour
hospit
patient
inflamm
nonbacteri
origin
patient
bacteri
infect
six
patient
without
bacteri
infect
three
bacteri
infect
die
day
admiss
six
month
patient
bacteri
infect
eight
patient
bacteri
infect
die
individu
baselin
valu
median
level
six
biomark
shown
figur
comput
specif
sensit
posit
neg
predict
valu
auc
singl
marker
composit
marker
regard
diagnosi
bacteri
infect
shown
tabl
correspond
roc
curv
shown
figur
sixmark
test
perform
significantli
better
singl
marker
p
crp
p
five
remain
marker
addit
analysi
abil
singl
marker
discrimin
infect
kind
infect
appar
figur
patient
parasit
plasmodium
falciparum
infect
high
concentr
crp
pct
particular
effect
omit
patient
auc
two
marker
determin
analysi
identifi
auc
ci
ci
crp
pct
respect
regard
discrimin
bacteri
nonbacteri
caus
inflamm
sever
marker
may
affect
immunedefici
condit
therefor
ancillari
analysi
conduct
patient
solid
tumour
haematolog
malign
hiv
infect
leucocyt
count
cellsl
treat
immunosuppress
exclud
analysi
abil
marker
diagnos
bacteri
infect
remain
virtual
unchang
none
singl
marker
auc
chang
data
shown
investig
diagnost
accuraci
six
singl
marker
two
composit
marker
relev
subgroup
analysi
patient
diagnos
copd
asthma
acut
exacerb
pneumonia
exclud
addit
abil
singl
marker
predict
cultureproven
bacteraemia
test
three
marker
greatest
auc
pct
crp
mif
auc
tabl
site
infect
pathogen
isol
respiratori
system
streptococcu
pneumonia
legionella
pneumonia
present
studi
demonstr
signific
gain
discrimin
power
diagnost
sepsi
marker
linear
combin
yield
highest
auc
employ
addit
patient
admit
medic
emerg
depart
depart
infecti
diseas
found
mif
supar
singl
marker
limit
diagnost
power
discrimin
bacteri
nonbacteri
caus
inflamm
howev
combin
crp
pct
neutrophil
count
high
auc
achiev
major
studi
new
sepsi
biomark
examin
biomark
one
time
measur
plasma
concentr
put
marker
individu
assay
carri
consider
burden
term
time
cost
sampl
volum
thu
limit
abil
examin
systemat
potenti
multipl
marker
combin
howev
xmap
technolog
provid
possibl
quantifi
multipl
protein
simultan
solut
phase
use
flow
cytometri
allow
research
profil
multipl
marker
diagnost
prognost
purpos
simultan
monitor
chang
time
marker
evalu
efficaci
treatment
techniqu
measur
multipl
marker
simultan
present
complex
diagnost
challeng
sepsi
rais
anoth
question
one
optim
combin
inform
multipl
marker
power
combin
multipl
sepsi
marker
recogn
earlier
studi
use
inform
suboptim
quantit
approach
identifi
optim
combin
sever
statist
studi
address
problem
combin
correl
diagnost
test
maxim
discriminatori
power
includ
logist
regress
linear
nonlinear
discrimin
analys
identifi
linear
combin
marker
yield
greatest
auc
model
deriv
score
specif
decis
rule
decis
tree
bayesian
decis
make
neural
network
combin
diagnost
marker
appear
use
approach
improv
accuraci
diagnos
sepsi
patient
sir
may
applic
complex
diseas
well
use
roc
curv
comparison
auc
singl
marker
becom
widespread
howev
although
statist
techniqu
need
identifi
combin
roc
curv
multipl
marker
yield
greatest
auc
avail
year
use
limit
studi
appli
statist
techniqu
develop
su
liu
found
increas
accuraci
diagnost
test
combin
diagnos
alzheim
diseas
prostat
cancer
respect
tabl
accuraci
biomark
sensit
ci
specif
ci
auc
ci
specif
specif
howev
import
rememb
hunt
larger
auc
might
alway
clinic
relev
case
gain
associ
low
sensit
specif
observ
studi
sensit
pct
predefin
clinic
relev
specif
second
highest
sixmark
test
higher
sensit
comparison
auc
pct
lower
auc
sixmark
test
threemark
test
crp
promis
result
diagnost
sepsi
marker
report
recent
year
gibot
cowork
measur
plasma
sampl
icu
patient
sir
suspect
infect
found
abl
diagnos
infect
sensit
ci
specif
ci
larg
differ
two
patient
cohort
term
spectrum
sever
diseas
known
previou
studi
diagnost
accuraci
sever
sepsi
marker
highli
depend
set
test
base
data
studi
seem
pct
particular
exhibit
superior
perform
crp
use
icu
might
well
case
addit
differ
analyt
method
plasma
anticoagul
plasma
sampl
process
procedur
use
regard
shown
halflif
plasma
short
hour
handl
procedur
present
studi
might
slow
recent
publish
find
plasma
patient
pneumonia
copd
asthma
set
similar
indic
differ
admiss
level
copd
pneumonia
patient
although
auc
guidanc
antibiot
therapi
found
ci
almost
ident
auc
ci
achiev
subgroup
analysi
interest
find
patient
inflammatori
bowel
diseas
increas
concentr
observ
sever
diseas
compar
patient
mild
symptom
also
murin
airpouch
model
crystalinduc
acut
inflamm
monosodium
urat
monohydr
crystal
induc
high
concentr
base
present
data
marker
infect
seem
reason
conclud
studi
use
meticul
valid
assay
clinic
relev
patient
group
need
studi
investig
use
pct
crp
medic
emerg
depart
found
diagnost
perform
crp
pct
similar
observ
studi
regard
diagnos
bacteraemia
particular
pct
exhibit
excel
diagnost
abil
accord
suggest
notion
pct
superior
crp
diagnos
system
infect
low
diagnost
accuraci
pct
diagnos
bacteri
infect
observ
studi
partli
due
five
patient
infect
p
falciparum
shown
analysi
group
omit
despit
studi
strength
howev
sever
limit
deserv
consider
probabl
oversimplif
use
linear
model
combin
marker
quadrat
cubic
transform
biomark
might
improv
diagnost
accuraci
use
clinic
criteria
microbiolog
evid
might
difficult
ascertain
precis
caus
sir
patient
might
introduc
misclassif
bia
expert
panel
disregard
measur
leucocyt
crp
studi
diagnost
sepsi
marker
total
blind
achiev
measur
integr
part
routin
monitor
infecti
diseas
patient
valu
reflect
way
patient
treat
might
lead
incorpor
bia
thu
overestim
diagnost
power
two
marker
compar
marker
test
although
reflect
statist
signific
differ
concentr
marker
patient
known
versu
unknown
bacteri
infect
thu
seem
marker
afford
preferenti
condit
classif
fact
sampl
collect
antibiot
therapi
initi
might
weaken
result
marker
short
halflif
would
affect
marker
long
halflif
patient
dementia
mental
diseas
could
particip
studi
need
inform
written
consent
know
whether
result
valid
import
group
patient
final
result
may
appli
patient
communityacquir
infect
requir
hospit
icu
directli
admiss
may
valid
icu
patient
result
demonstr
combin
inform
sever
sepsi
marker
simpl
may
significantli
improv
clinician
abil
differenti
patient
bacteri
infect
system
inflamm
nonbacteri
origin
admit
would
great
import
patient
diagnosi
clinic
clear
cut
often
case
special
depart
infecti
diseas
bear
mind
rapid
adequ
treatment
patient
suspect
bacteri
sepsi
requir
accur
diagnosi
combin
inform
sever
marker
appear
improv
diagnost
accuraci
detect
bacteri
versu
nonbacteri
caus
system
inflamm
cohort
patient
sir
admit
medic
emerg
depart
depart
infecti
diseas
suspect
communityacquir
infect
singl
measur
supar
mif
appear
limit
power
diagnost
marker
bacteri
infect
crp
pct
neutrophil
count
accept
diagnost
power
diagnosi
communityacquir
bacteri
infect
patient
sir
admit
depart
infecti
diseas
diagnost
accuraci
crp
pct
sixmark
test
higher
subgroup
patient
suspect
pneumonia
group
whole
